| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$41,072 ) |
| | 2025 | 2024 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 000 | 9 | NIH | 3/31/2025 | $0 |
| | 2025 | 2024 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01DA059822 | TRANSFORM - Transforming the evidence base on estimating prevalence of opioid use disorder and expanded access to interventions to prevent drug related deaths: an international data linkage study | 000 | 1 | NIH | 3/13/2025 | $0 |
| | 2025 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R21AI150331 | Accurately defining the distribution of the genetically intact and potentially replication-competent HIV-1 reservoir during the first 3 years of integrase inhibitor containing antiretroviral therapy | 000 | 2 | NIH | 1/13/2025 | $0 |
| | 2025 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01DA044170 | Using existing data to understand and ameliorate risk in opioid agonist therapy | 000 | 3 | NIH | 10/1/2024 | -$41,072 |
|
| Issue Date FY: 2024 ( Subtotal = $3,264,931 ) |
| | 2024 | 2024 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01DA059822 | TRANSFORM - Transforming the evidence base on estimating prevalence of opioid use disorder and expanded access to interventions to prevent drug related deaths: an international data linkage study | 000 | 1 | NIH | 8/9/2024 | $688,653 |
| | 2024 | 2024 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01AG057531 | A global epidemiology of cognitive impairment and dementia due to Alzheimer's disease and related disorders: the COSMIC Collaboration | 001 | 3 | NIH | 7/23/2024 | $1,640,425 |
| | 2024 | 2024 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 001 | 9 | NIH | 6/28/2024 | $454,977 |
| | 2024 | 2024 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01CA251443 | Engineered microtumor arrays for development of combination therapies | 000 | 5 | NIH | 6/26/2024 | $106,589 |
| | 2024 | 2023 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 000 | 8 | NIH | 12/19/2023 | $0 |
| | 2024 | 2023 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01AG057531 | A global epidemiology of cognitive impairment and dementia due to Alzheimer's disease and related disorders: the COSMIC Collaboration | 000 | 2 | NIH | 1/8/2024 | $374,287 |
| | 2024 | 2022 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R21AI162141 | Characterisation and harnessing the CD8+ Tissue Resident Memory T cell response in HPV-driven anal neoplasia. | 000 | 2 | NIH | 7/10/2024 | $0 |
| | 2024 | 2022 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R03CA251976 | Targeted therapy against TERT oncogene-rearranged neuroblastoma | 000 | 2 | NIH | 3/4/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,481,041 ) |
| | 2023 | 2023 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 001 | 8 | NIH | 9/13/2023 | $9,100 |
| | 2023 | 2023 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01CA251443 | Engineered microtumor arrays for development of combination therapies | 000 | 4 | NIH | 8/21/2023 | $145,949 |
| | 2023 | 2023 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01AG057531 | A global epidemiology of cognitive impairment and dementia due to Alzheimer's disease and related disorders: the COSMIC Collaboration | 000 | 2 | NIH | 8/18/2023 | $1,018,787 |
| | 2023 | 2023 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 000 | 8 | NIH | 7/4/2023 | $445,877 |
| | 2023 | 2022 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R21AI162141 | Characterisation and harnessing the CD8+ Tissue Resident Memory T cell response in HPV-driven anal neoplasia. | 000 | 2 | NIH | 6/14/2023 | $0 |
| | 2023 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R21AI150331 | Accurately defining the distribution of the genetically intact and potentially replication-competent HIV-1 reservoir during the first 3 years of integrase inhibitor containing antiretroviral therapy | 000 | 2 | NIH | 6/13/2023 | $0 |
| | 2023 | 2020 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | RF1AG057531 | COSMIC: An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethno-racial groups and geographical settings | 000 | 1 | NIH | 10/1/2022 | -$138,672 |
| | 2023 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01DA040506 | A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection (the REACT Study) | 000 | 5 | NIH | 11/23/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $881,289 ) |
| | 2022 | 2022 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 003 | 7 | NIH | 8/11/2022 | $445,877 |
| | 2022 | 2022 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R03CA251976 | Targeted therapy against TERT oncogene-rearranged neuroblastoma | 000 | 2 | NIH | 7/29/2022 | $54,000 |
| | 2022 | 2022 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R21AI162141 | Characterisation and harnessing the CD8+ Tissue Resident Memory T cell response in HPV-driven anal neoplasia. | 000 | 2 | NIH | 7/14/2022 | $121,306 |
| | 2022 | 2022 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01CA251443 | Engineered microtumor arrays for development of combination therapies | 000 | 3 | NIH | 7/18/2022 | $260,106 |
| | 2022 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R21AI150331 | Accurately defining the distribution of the genetically intact and potentially replication-competent HIV-1 reservoir during the first 3 years of integrase inhibitor containing antiretroviral therapy | 000 | 2 | NIH | 4/25/2022 | $0 |
| | 2022 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 000 | 6 | NIH | 10/28/2021 | $20,091 |
| | 2022 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 001 | 5 | NIH | 10/28/2021 | -$20,091 |
| | 2022 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 002 | 6 | NIH | 12/8/2021 | $0 |
| | 2022 | 2020 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | RF1AG057531 | COSMIC: An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethno-racial groups and geographical settings | 001 | 1 | NIH | 1/31/2022 | $0 |
| | 2022 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01DA044170 | Using existing data to understand and ameliorate risk in opioid agonist therapy | 000 | 3 | NIH | 4/12/2022 | $0 |
| | 2022 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01DA040506 | A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection (the REACT Study) | 000 | 5 | NIH | 12/13/2021 | $0 |
| | 2022 | 2017 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | RF1AG057531 | COSMIC: An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethno-racial groups and geographical settings | 000 | 1 | NIH | 1/31/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,226,051 ) (Continued on the next page) |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 005 | 6 | NIH | 8/17/2021 | $454,976 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 006 | 5 | NIH | 8/17/2021 | $0 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R21AI150331 | Accurately defining the distribution of the genetically intact and potentially replication-competent HIV-1 reservoir during the first 3 years of integrase inhibitor containing antiretroviral therapy | 000 | 2 | NIH | 5/24/2021 | $134,540 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R01CA251443 | Engineered microtumor arrays for development of combination therapies | 000 | 2 | NIH | 6/30/2021 | $241,920 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R03CA251976 | Targeted therapy against TERT oncogene-rearranged neuroblastoma | 001 | 1 | NIH | 9/15/2021 | -$54,000 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R03CA251976 | Targeted therapy against TERT oncogene-rearranged neuroblastoma | 000 | 1 | NIH | 7/16/2021 | $54,000 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R03CA251976 | Targeted therapy against TERT oncogene-rearranged neuroblastoma | 001 | 1 | NIH | 9/15/2021 | $54,000 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R21AI162141 | Characterisation and harnessing the CD8+ Tissue Resident Memory T cell response in HPV-driven anal neoplasia. | 000 | 1 | NIH | 6/21/2021 | $148,306 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 001 | 5 | NIH | 2/3/2021 | $192,309 |
| | 2021 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R21CA226959 | Eradication of MYCN-amplified neuroblastoma by targeting the interaction between a long noncoding RNA and its binding protein | 000 | 2 | NIH | 1/4/2021 | $0 |
| | 2021 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 004 | 5 | NIH | 8/17/2021 | $0 |
| | 2021 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 000 | 5 | NIH | 2/3/2021 | $0 |
| | 2021 | 2018 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 003 | 4 | NIH | 7/28/2021 | $0 |
|
Friday, May 9, 2025
5/9/2025
